Table of Contents
International Journal of Proteomics
Volume 2012, Article ID 921901, 10 pages
http://dx.doi.org/10.1155/2012/921901
Review Article

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care

1Department of Surgery, Tokyo Medical University, 6-7-1 Nishi Shinjuku Shinjuku-ku, Tokyo 160-0023, Japan
2Graduate School of Medical Science, Yokohama City University, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
3Medical ProteoScope, 1-6 Suehiro-cho, Tsurumi-ku, Yokohamashi, Kanagaewa, 230-0045, Japan
4Thoracic Surgery, Niizashiki Chuo General Hospital, 7-2 1-chome, Tohoku, Niiza, Saitama 352-0001, Japan

Received 9 December 2011; Accepted 28 February 2012

Academic Editor: Tadashi Kondo

Copyright © 2012 Toshihide Nishimura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Kaneko, “The society created by the longevity revolution–historical development and associated issues,” Japanese Journal of Population, vol. 9, no. 1, pp. 135–154, 2009. View at Google Scholar
  2. H. Kato, T. Nishimura, T. Hirano et al., “A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare,” Journal of Proteome Research, vol. 10, no. 1, pp. 51–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer),” Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Kudoh, H. Kato, Y. Nishiwaki et al., “Interstitial lung disease in japanese patients with lung cancer: a cohort and nested case-control study,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 12, pp. 1348–1357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Davis, L. Furstenthal, A. A. Desai et al., “The microeconomics of personalized medicine: today's challenge and tomorrow's promise,” Nature Reviews Drug Discovery, vol. 8, no. 4, pp. 279–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Hornberger, L. E. Cosler, and G. H. Lyman, “Economic analysis of targeting chemotherapy using a 21-gene rt-pcr assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer,” American Journal of Managed Care, vol. 11, no. 5, pp. 313–324, 2005. View at Google Scholar · View at Scopus
  7. R. Lutter, A. McWilliam, and C. Nardinelli, Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin, 2006.
  8. H. Keshishian, T. Addona, M. Burgess, E. Kuhn, and S. A. Carr, “Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution,” Molecular and Cellular Proteomics, vol. 6, no. 12, pp. 2212–2229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. D. Jaffe, H. Keshishian, B. Chang, T. A. Addona, M. A. Gilette, and S. A. Carr, “Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification,” Molecular and Cellular Proteomics, vol. 7, no. 10, pp. 1952–1962, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. A. Addona, S. E. Abbatiello, B. Schilling et al., “Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma,” Nature Biotechnology, vol. 27, no. 7, pp. 633–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. H. Johnson, L. Fehrenbacher, W. F. Novotny et al., “Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2184–2191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Peták, R. Schwab, L. Örfi, L. Kopper, and G. Kéri, “Integrating molecular diagnostics into anticancer drug discovery,” Nature Reviews Drug Discovery, vol. 9, no. 7, pp. 523–535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. E. Johnson and P. A. Jänne, “Selecting patients for epidermal growth factor receptor inhibitor treatment: a fish story or a tale of mutations?” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6813–6816, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. G. Paez, P. A. Jänne, J. C. Lee et al., “Egfr mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Marko-Varga, A. Ogiwara, T. Nishimura et al., “Personalized medicine and proteomics: lessons from non-small cell lung cancer,” Journal of Proteome Research, vol. 6, no. 8, pp. 2925–2935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Hirano, H. Kato, M. Maeda et al., “Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker,” International Journal of Cancer, vol. 117, no. 3, pp. 460–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. “Committee declaration of the drug pricing within the Ministry of Health Labour and Welfare (MHLW),” Chu-i-kyo, Yaku-1483, 2009.
  21. G. Raghu, F. Nyberg, and G. Morgan, “The epidemiology of interstitial lung disease and its association with lung cancer,” British Journal of Cancer, vol. 91, no. 2, pp. S3–S10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Azuma and S. Kudoh, “High prevalence of drug-induced pneumonia in japan,” Japan Medical Association Journal, vol. 50, no. 5, pp. 405–411, 2007. View at Google Scholar · View at Scopus
  23. L. C. Koo, J. A. Clark, C. P. Quesenberry et al., “National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the who international drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions,” Pharmacoepidemiology and Drug Safety, vol. 14, no. 11, pp. 775–787, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Inoue, Y. Saijo, M. Maemondo et al., “Severe acute interstitial pneumonia and gefitinib,” Lancet, vol. 361, no. 9352, pp. 137–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kudoh, K. Takeda, K. Nakagawa et al., “Phase iii study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the west japan thoracic oncology group trial (WJTOG 9904),” Journal of Clinical Oncology, vol. 24, no. 22, pp. 3657–3663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Ando, I. Okamoto, N. Yamamoto et al., “Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib,” Journal of Clinical Oncology, vol. 24, no. 16, pp. 2549–2556, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Danson, F. Blackhall, P. Hulse, and M. Ranson, “Interstitial lung disease in lung cancer: separating disease progression from treatment effects,” Drug Safety, vol. 28, no. 2, pp. 103–113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Nishimura, M. Nomura, T. Fukuda et al., “MRM MS-based assays to identify biomarkers for lung carcinoma of large-cell neuroendocrine (LCNEC),” in Proceedings of the 3rd European Proteomics Association Congress (EuPA '09), G. Marko-Varga and T. Laurell, Eds., pp. 62–66, Ook-Press, Stockholm, Sweden, 2009.
  29. A. Ogiwara, T. Kawakami, K. Nagasaka et al., “Keys to success for large-scale proteomics analysis conducted with a clinical study,” in Proceedings of the 3rd EuPA Congress, G. Marko-Varga and T. Laurell, Eds., pp. 252–254, Ook-Press, Stockholm, Sweden, 2009.
  30. F. Nyberg, A. Ogiwara, C. G. Harbron et al., “Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated japanese lung cancer patients,” Plos one, vol. 6, no. 7, Article ID e22062, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Nomura, T. Fukuda, K. Fujii et al., “Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study,” Journal of Clinical Bioinformatics, vol. 1, article 23, 2011. View at Google Scholar
  32. E. Brambilla, “Who 1999 classification of lung cancers: a guided tour,” Annales De Pathologie, vol. 19, no. 5, supplement, pp. S47–49, 1999. View at Google Scholar · View at Scopus
  33. D. A. Prieto, B. L. Hood, M. M. Darfler et al., “Liquid tissue: proteomic profiling of formalin-fixed tissues,” Biotechniques., vol. Suppl, pp. 32–35, 2005. View at Google Scholar · View at Scopus
  34. B. L. Hood, T. P. Conrads, and T. D. Veenstra, “Unravelling the proteome of formalin-fixed paraffin-embedded tissue,” Briefings in Functional Genomics and Proteomics, vol. 5, no. 2, pp. 169–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. L. Hood, T. P. Conrads, and T. D. Veenstra, “Mass spectrometric analysis of formalin-fixed paraffin-embedded tissue: unlocking the proteome within,” Proteomics, vol. 6, no. 14, pp. 4106–4114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Picotti, O. Rinner, R. Stallmach et al., “High-throughput generation of selected reaction-monitoring assays for proteins and proteomes,” Nature Methods, vol. 7, no. 1, pp. 43–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Surinova, R. Schiess, R. Hüttenhain, F. Cerciello, B. Wollscheid, and R. Aebersold, “On the development of plasma protein biomarkers,” Journal of Proteome Research, vol. 10, no. 1, pp. 5–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. N. L. Anderson, N. G. Anderson, T. W. Pearson et al., “A human proteome detection and quantitation project,” Molecular and Cellular Proteomics, vol. 8, no. 5, pp. 883–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Á. Végvári and G. Marko-Varga, “Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer,” Chemical Reviews, vol. 110, no. 5, pp. 3278–3298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Marko-Varga, T. E. Fehniger, M. Rezeli, B. Döme, T. Laurell, and Á. Végvári, “Drug localization in different lung cancer phenotypes by maldi mass spectrometry imaging,” Journal of Proteomics, vol. 74, no. 7, pp. 982–992, 2011. View at Publisher · View at Google Scholar · View at Scopus